Clinical trial NCT05705700: Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)
Official title: Biomarker Study Targeting Abiraterone Metabolites and Polymporphisms in Men With PSA Progression on Abiraterone for the Treatment of Castration Resistant or Castration Sensitive Prostate Cancer (The Bio-STAMP Study)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Prostate Cancer
Lead sponsor: Masonic Cancer Center, University of Minnesota
Sponsor class: OTHER
First posted: 2023-01-31
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a multicenter, Phase II randomized biomarker-based therapeutic study in metastatic prostate cancer experiencing prostate specific antigen (PSA) only progression (without visceral, bone or lymph node progression) while on abiraterone therapy.


Eligibility criteria: Inclusion Criteria:

* Histological or cytological evidence of adenocarcinoma of the prostate
* Undergone orchiectomy, or have been on luteinizing hormone-releasing hormone (LHRH) agonists or antagonists for at least 3 months prior to study enrollment. Patients on LHRH agonists/antagonists must remain on these agents for the duration of the study.
* Currently receiving abiraterone (ZYTIGA or FDA approved generic) in the castration sensitive (CSPC) or castration resistant (CRPC) setting with PSA progression in the absence of visceral, bone or lymph node progression. PSA progression is defined as an increase in the PSA level of more than 50% above the nadir with two consecutive increases at least 2 weeks apart (based on Prostate Cancer Working Group Criteria, version 3 (PCWG3).
* Minimum PSA must be ≥1.0 ng/dL.
* Age 18 years of age or older.
* ECOG performance status 0 or 1.
* Have adequate organ function confirmed by the following laboratory values obtained within 14 days prior to enrollment:

  * absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L
  * platelets ≥ 100 × 10\^9/L
  * hemoglobin ≥ 10 g/dL, independent of transfusion ≤14 days of screening
  * aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN); if liver metastases, then ≤ 5 × ULN
  * total bilirubin ≤ 1.5 × ULN; \< 2 × ULN if hyperbilirubinemia is due to Gilbert's syndrome
  * serum albumin ≥ 30 g/L (3.0 g/dL)
  * Serum creatinine ≤ 1.5 x ULN; OR estimated glomerular filtration rate (GFR) ≥ 45 mL/min using the Cockcroft Gault formula
* Participants with partners of childbearing potential must be willing to use at least two forms of effective birth control (one form must be a barrier method) during the dutasteride treatment period and for 6 months after last dose or 3 weeks after the last dose of abiraterone whichever is longer. Persons are considered to be of childbearing potential unless one or the following applies:

  * Is postmenopausal, defined as no menses for at least 12 months without an alternative medical cause
  * Considered permanently sterile. Permanent sterilization includes hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy.
* Voluntary written consent prior to the performance of any research related activit

Exclusion Criteria:

* Previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to 5 alpha-reductase inhibitors (i.e. finasteride).
* Prior use of Enzalutamide, Apalutamide, or Darolutamide for the treatment of prostate cancer.

Primary outcomes:
measure: Number of patients with radiographic progression free survival (rPFS) rate
timeFrame: 24 Weeks after study treatment
Secondary outcomes:
measure: Determine overall survival (OS)
timeFrame: 24 months from start of treatment assignment
measure: Number of patients with a PSA decline of ≥ 50%
timeFrame: 24 weeks of adding of adding high-dose dutasteride
Other outcomes:
Locations:
Study officials:
affiliation: Masonic Cancer Center, Univeristy of Minnesota
name: Charles Ryan, MD
role: PRINCIPAL_INVESTIGATOR
References: